Comparison between Canara HSBC Life IPO and Corona Remedies IPO.
Canara HSBC Life IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Corona Remedies IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Canara HSBC Life IPO is up to ₹2,517.50 Cr whereas the issue size of the Corona Remedies IPO is up to ₹655.37 Cr. The final issue price of Canara HSBC Life IPO is ₹106.00 per share and of Corona Remedies IPO is ₹1,062.00 per share.
| Canara HSBC Life IPO | Corona Remedies IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹100.00 per share | ₹1,008.00 per share |
| Issue Price (Upper) | ₹106.00 per share | ₹1,062.00 per share |
| Issue Price (Final) | ₹106.00 per share | ₹1,062.00 per share |
| Discount (Retail) | ||
| Discount (Employee) | ₹10.00 per share | ₹54.00 per share |
| Market Lot Size | 140 shares | 14 shares |
| Fresh Issue Size | 0 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 23,75,00,000 shares | 61,74,051 shares |
| OFS Issue Size (Amount) | up to ₹2,517.50 Cr | up to ₹655.37 Cr |
| Issue Size Total | 23,75,00,000 shares | 61,74,051 shares |
| Issue Size Total (Amount) | up to ₹2,517.50 Cr | up to ₹655.37 Cr |
Canara HSBC Life IPO opens on Oct 10, 2025, while Corona Remedies IPO opens on Dec 08, 2025. The closing date of Canara HSBC Life IPO and Corona Remedies IPO is Oct 14, 2025, and Dec 10, 2025, respectively.
| Canara HSBC Life IPO | Corona Remedies IPO | |
|---|---|---|
| Anchor Bid Date | Oct 09, 2025 | Dec 05, 2025 |
| Issue Open | Oct 10, 2025 | Dec 08, 2025 |
| Issue Close | Oct 14, 2025 | Dec 10, 2025 |
| Basis Of Allotment (Tentative) | Oct 15, 2025 | Dec 11, 2025 |
| Initiation of Refunds (Tentative) | Oct 16, 2025 | Dec 12, 2025 |
| Credit of Share (Tentative) | Oct 16, 2025 | Dec 12, 2025 |
| Listing date (Tentative) | Oct 17, 2025 | Dec 15, 2025 |
| Anchor Lockin End date 1 | Nov 13, 2025 | Jan 09, 2026 |
| Anchor Lockin End date 2 | Jan 12, 2026 | Mar 10, 2026 |
Canara HSBC Life IPO P/E ratio is 86.08, as compared to Corona Remedies IPO P/E ratio of 43.47.
| Canara HSBC Life IPO | Corona Remedies IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)Canara HSBC Life Insurance Co.Ltd.'s revenue decreased by 3% and profit after tax (PAT) rose by 3% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated Consolidated)Corona Remedies Ltd.'s revenue increased by 18% and profit after tax (PAT) rose by 65% between the financial year ending with March 31, 2025 and March 31, 2024.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 77 | 72.5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 62 | 69 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 86.08 | 43.47 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹10070.00 Cr. | ₹6495.20 Cr. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 7.71% | 27.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 41.32% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.10 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹1.23 | ₹24.43 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 7.97% | 24.65% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Canara HSBC Life IPO Retail Individual Investors (RII) are offered 8,25,82,500 shares while in Corona Remedies IPO retail investors are offered 8,25,82,500 shares. Qualified Institutional Buyers (QIB) are offered 4,71,90,000 shares in Canara HSBC Life IPO and 12,23,203 shares in Corona Remedies IPO.
| Canara HSBC Life IPO | Corona Remedies IPO | |
|---|---|---|
| Anchor Investor Reservation | 7,07,85,000 shares | 18,34,804 shares |
| Market Maker Reservation | 0 shares | 0 shares |
| QIB | 4,71,90,000 shares | 12,23,203 shares |
| NII | 3,53,92,500 shares | 9,17,403 shares |
| RII | 8,25,82,500 shares | 21,40,606 shares |
| Employee | 15,50,000 shares | 58,035 shares |
| Others | ||
| Total | 23,75,00,000 shares | 61,74,051 shares |
Canara HSBC Life IPO subscribed 2.30x in total, whereas Corona Remedies IPO subscribed 144.54x.
| Canara HSBC Life IPO | Corona Remedies IPO | |
|---|---|---|
| QIB (times) | 7.05x | 293.80x |
| NII (times) | 0.33x | 220.18x |
| Big NII (times) | 0.28x | 246.67x |
| Small NII (times) | 0.44x | 167.20x |
| RII (times) | 0.42x | 30.39x |
| Employee (times) | 2.06x | 15.56x |
| Other (times) | ||
| Total (times) | 2.30x | 144.54x |
